2016
DOI: 10.1016/j.jns.2016.09.050
|View full text |Cite
|
Sign up to set email alerts
|

Antioxidant and inflammatory biomarkers for the identification of prodromal Parkinson's disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
7
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 19 publications
(7 citation statements)
references
References 37 publications
0
7
0
Order By: Relevance
“…The authors suggested that low GSH concentrations may be a promising blood biomarker for an early PD diagnosis. 23 However, the cross-sectional design, the small sample size, and the fact that pPD was not defined using the MDS-proposed pPD probability score but, rather, considering only one prodromal marker (RBD), limit the robustness and generalizability of the results. Our findings support the potential role of plasma GSH as a biomarker during the early stages of PD, as we demonstrated its relationship with pPD probability trajectories in a random sample of community-dwelling older adults.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The authors suggested that low GSH concentrations may be a promising blood biomarker for an early PD diagnosis. 23 However, the cross-sectional design, the small sample size, and the fact that pPD was not defined using the MDS-proposed pPD probability score but, rather, considering only one prodromal marker (RBD), limit the robustness and generalizability of the results. Our findings support the potential role of plasma GSH as a biomarker during the early stages of PD, as we demonstrated its relationship with pPD probability trajectories in a random sample of community-dwelling older adults.…”
Section: Discussionmentioning
confidence: 99%
“…In a cross‐sectional study including 15 participants with PD, 11 with idiopathic RBD (ie, a prodromal PD marker), and 12 healthy controls, blood reduced GSH (but not plasma GSH) concentrations were independently associated with overt PD and RBD. The authors suggested that low GSH concentrations may be a promising blood biomarker for an early PD diagnosis 23 . However, the cross‐sectional design, the small sample size, and the fact that pPD was not defined using the MDS‐proposed pPD probability score but, rather, considering only one prodromal marker (RBD), limit the robustness and generalizability of the results.…”
Section: Discussionmentioning
confidence: 99%
“…In neutrophil granulocytes, PD patients were found to have altered mitochondrial mass and membrane potential, as well as increased oxidative stress . Prigione et al (2006) found increased total ROS levels in PD patient PBMCs compared with controls, and a recent pilot study demonstrated lower whole‐blood levels of reduced glutathione in RBD as well as PD patients …”
Section: Discussionmentioning
confidence: 99%
“…In a similar manner, the treatment further increased the already-high levels of the anti-inflammatory cytokine IL-10 in PBMCs. In addition, we also tested neopterin, a sensitive marker of immune system activation for neurodegenerative disorders such as Parkinson's disease [42], which was not previously reported in X-ALD. We found elevated levels of neopterin in the CSF before treatment; these levels were significantly decreased with antioxidant treatment in all the subjects from whom CSF was available (Fig.…”
Section: Inflammatory Markersmentioning
confidence: 99%